$SGXP Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in SGX PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in SGX PHARMACEUTICALS, INC.. Get notifications about new insider transactions in SGX PHARMACEUTICALS, INC. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Buy | M | 0.00 | 1,563 | 0 | 17,971 | 16.4 K to 18 K (+9.53 %) |
| Nov 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Option Exercise | M | 0.00 | 1,562 | 0 | 39,063 | |
| Nov 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 6.50 | 781 | 5,077 | 17,971 | 18.8 K to 18 K (-4.16 %) |
| Nov 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Buy | M | 0.00 | 1,562 | 0 | 18,752 | 17.2 K to 18.8 K (+9.09 %) |
| Oct 15 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Option Exercise | M | 0.00 | 1,562 | 0 | 42,188 | |
| Oct 15 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 6.43 | 400 | 2,572 | 16,408 | 16.8 K to 16.4 K (-2.38 %) |
| Oct 15 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 6.42 | 200 | 1,284 | 16,808 | 17 K to 16.8 K (-1.18 %) |
| Oct 15 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 6.41 | 181 | 1,160 | 17,008 | 17.2 K to 17 K (-1.05 %) |
| Oct 15 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Buy | M | 0.00 | 1,562 | 0 | 17,189 | 15.6 K to 17.2 K (+10.00 %) |
| Oct 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Option Exercise | M | 0.00 | 1,563 | 0 | 40,625 | |
| Oct 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 6.20 | 781 | 4,842 | 17,190 | 18 K to 17.2 K (-4.35 %) |
| Oct 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Buy | M | 0.00 | 1,563 | 0 | 17,971 | 16.4 K to 18 K (+9.53 %) |
| Sep 17 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Option Exercise | M | 0.00 | 1,563 | 0 | 43,750 | |
| Sep 17 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 6.20 | 781 | 4,842 | 15,627 | 16.4 K to 15.6 K (-4.76 %) |
| Sep 17 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Buy | M | 0.00 | 1,563 | 0 | 16,408 | 14.8 K to 16.4 K (+10.53 %) |
| Sep 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Option Exercise | M | 0.00 | 1,562 | 0 | 42,188 | |
| Sep 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 6.10 | 21 | 128 | 16,408 | 16.4 K to 16.4 K (-0.13 %) |
| Sep 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 6.10 | 200 | 1,220 | 16,429 | 16.6 K to 16.4 K (-1.20 %) |
| Sep 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 6.20 | 560 | 3,472 | 16,629 | 17.2 K to 16.6 K (-3.26 %) |
| Sep 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Buy | M | 0.00 | 1,562 | 0 | 17,189 | 15.6 K to 17.2 K (+10.00 %) |
| Aug 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Option Exercise | M | 0.00 | 1,562 | 0 | 45,313 | |
| Aug 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 6.45 | 112 | 722 | 14,845 | 15 K to 14.8 K (-0.75 %) |
| Aug 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 6.40 | 669 | 4,282 | 14,957 | 15.6 K to 15 K (-4.28 %) |
| Aug 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Buy | M | 0.00 | 1,562 | 0 | 15,626 | 14.1 K to 15.6 K (+11.11 %) |
| Aug 07 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Option Exercise | M | 0.00 | 1,563 | 0 | 43,750 | |
| Aug 07 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 6.56 | 181 | 1,187 | 15,627 | 15.8 K to 15.6 K (-1.14 %) |
| Aug 07 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 6.70 | 600 | 4,020 | 15,808 | 16.4 K to 15.8 K (-3.66 %) |
| Aug 07 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Buy | M | 0.00 | 1,563 | 0 | 16,408 | 14.8 K to 16.4 K (+10.53 %) |
| Jul 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Option Exercise | M | 0.00 | 1,563 | 0 | 46,875 | |
| Jul 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 6.05 | 781 | 4,725 | 14,064 | 14.8 K to 14.1 K (-5.26 %) |
| Jul 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Buy | M | 0.00 | 1,563 | 0 | 14,845 | 13.3 K to 14.8 K (+11.77 %) |
| Jul 09 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Option Exercise | M | 0.00 | 1,562 | 0 | 45,313 | |
| Jul 09 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 5.33 | 781 | 4,163 | 14,845 | 15.6 K to 14.8 K (-5.00 %) |
| Jul 09 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Buy | M | 0.00 | 1,562 | 0 | 15,626 | 14.1 K to 15.6 K (+11.11 %) |
| Jun 19 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Option Exercise | M | 0.00 | 1,562 | 0 | 48,438 | |
| Jun 19 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 5.18 | 100 | 518 | 13,282 | 13.4 K to 13.3 K (-0.75 %) |
| Jun 19 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 5.15 | 100 | 515 | 13,382 | 13.5 K to 13.4 K (-0.74 %) |
| Jun 19 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 5.11 | 581 | 2,969 | 13,482 | 14.1 K to 13.5 K (-4.13 %) |
| Jun 19 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Buy | M | 0.00 | 1,562 | 0 | 14,063 | 12.5 K to 14.1 K (+12.50 %) |
| Jun 11 2007 | SGXP | SGX PHARMACEUTICAL ... | HENNEY CHRISTOPHER S | Director | Option Exercise | A | 5.21 | 10,000 | 52,100 | 30,000 | |
| Jun 11 2007 | SGXP | SGX PHARMACEUTICAL ... | HENNEY CHRISTOPHER S | Director | Option Exercise | A | 5.21 | 20,000 | 104,200 | 20,000 | |
| Jun 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Option Exercise | M | 0.00 | 1,563 | 0 | 46,875 | |
| Jun 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 5.30 | 781 | 4,139 | 14,064 | 14.8 K to 14.1 K (-5.26 %) |
| Jun 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Buy | M | 0.00 | 1,563 | 0 | 14,845 | 13.3 K to 14.8 K (+11.77 %) |
| May 18 2007 | SGXP | SGX PHARMACEUTICAL ... | BOCK LOUIS C | Director | Option Exercise | A | 5.03 | 10,000 | 50,300 | 10,000 | |
| May 18 2007 | SGXP | SGX PHARMACEUTICAL ... | EASTHAM KARIN | Director | Option Exercise | A | 5.03 | 10,000 | 50,300 | 20,000 | |
| May 18 2007 | SGXP | SGX PHARMACEUTICAL ... | HENNEY CHRISTOPHER S | Director | Option Exercise | A | 5.03 | 15,000 | 75,450 | 25,000 | |
| May 17 2007 | SGXP | SGX PHARMACEUTICAL ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | A | 5.03 | 10,000 | 50,300 | 10,000 | |
| May 17 2007 | SGXP | SGX PHARMACEUTICAL ... | Lathi Vijay K | Director | Option Exercise | A | 5.03 | 10,000 | 50,300 | 10,000 | |
| May 17 2007 | SGXP | SGX PHARMACEUTICAL ... | EASTHAM KARIN | Director | Option Exercise | A | 5.03 | 10,000 | 50,300 | 10,000 | |
| May 17 2007 | SGXP | SGX PHARMACEUTICAL ... | HENNEY CHRISTOPHER S | Director | Option Exercise | A | 5.03 | 10,000 | 50,300 | 10,000 | |
| May 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Option Exercise | M | 0.00 | 1,563 | 0 | 50,000 | |
| May 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 5.20 | 200 | 1,040 | 12,501 | 12.7 K to 12.5 K (-1.57 %) |
| May 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 5.19 | 100 | 519 | 12,701 | 12.8 K to 12.7 K (-0.78 %) |
| May 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 5.18 | 100 | 518 | 12,801 | 12.9 K to 12.8 K (-0.78 %) |
| May 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 5.17 | 381 | 1,970 | 12,901 | 13.3 K to 12.9 K (-2.87 %) |
| May 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Buy | M | 0.00 | 1,563 | 0 | 13,282 | 11.7 K to 13.3 K (+13.34 %) |
| May 08 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Option Exercise | M | 0.00 | 1,562 | 0 | 48,438 | |
| May 08 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 5.08 | 281 | 1,427 | 13,282 | 13.6 K to 13.3 K (-2.07 %) |
| May 08 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 5.00 | 500 | 2,500 | 13,563 | 14.1 K to 13.6 K (-3.56 %) |
| May 08 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Buy | M | 0.00 | 1,562 | 0 | 14,063 | 12.5 K to 14.1 K (+12.50 %) |
| Apr 17 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Option Exercise | M | 0.00 | 1,562 | 0 | 51,563 | |
| Apr 17 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 5.04 | 202 | 1,018 | 11,719 | 11.9 K to 11.7 K (-1.69 %) |
| Apr 17 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 5.02 | 200 | 1,004 | 11,921 | 12.1 K to 11.9 K (-1.65 %) |
| Apr 17 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 5.01 | 379 | 1,899 | 12,121 | 12.5 K to 12.1 K (-3.03 %) |
| Apr 17 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Buy | M | 0.00 | 1,562 | 0 | 12,500 | 10.9 K to 12.5 K (+14.28 %) |
| Apr 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Option Exercise | M | 0.00 | 1,563 | 0 | 50,000 | |
| Apr 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 4.61 | 781 | 3,600 | 12,501 | 13.3 K to 12.5 K (-5.88 %) |
| Apr 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Buy | M | 0.00 | 1,563 | 0 | 13,282 | 11.7 K to 13.3 K (+13.34 %) |
| Mar 15 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Option Exercise | M | 0.00 | 1,563 | 0 | 53,125 | |
| Mar 15 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 5.53 | 100 | 553 | 10,938 | 11 K to 10.9 K (-0.91 %) |
| Mar 15 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 5.53 | 681 | 3,766 | 11,038 | 11.7 K to 11 K (-5.81 %) |
| Mar 15 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Buy | M | 0.00 | 1,563 | 0 | 11,719 | 10.2 K to 11.7 K (+15.39 %) |
| Mar 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Option Exercise | M | 0.00 | 1,562 | 0 | 51,563 | |
| Mar 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 4.83 | 781 | 3,772 | 11,719 | 12.5 K to 11.7 K (-6.25 %) |
| Mar 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Buy | M | 0.00 | 1,562 | 0 | 12,500 | 10.9 K to 12.5 K (+14.28 %) |
| Feb 15 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Option Exercise | M | 0.00 | 1,562 | 0 | 54,688 | |
| Feb 15 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Sell | S | 5.36 | 781 | 4,186 | 10,156 | 10.9 K to 10.2 K (-7.14 %) |
| Feb 15 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Buy | M | 0.00 | 1,562 | 0 | 10,937 | 9.4 K to 10.9 K (+16.66 %) |
| Feb 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Option Exercise | M | 0.00 | 1,563 | 0 | 53,125 | |
| Feb 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Sell | S | 3.90 | 781 | 3,046 | 10,938 | 11.7 K to 10.9 K (-6.66 %) |
| Feb 05 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Buy | M | 0.00 | 1,563 | 0 | 11,719 | 10.2 K to 11.7 K (+15.39 %) |
| Jan 29 2007 | SGXP | SGX PHARMACEUTICAL ... | RUGG TERENCE ANTHONY | CMO & VP, Drug Deve ... | Option Exercise | A | 3.63 | 31,741 | 115,220 | 31,741 | |
| Jan 29 2007 | SGXP | SGX PHARMACEUTICAL ... | RUGG TERENCE ANTHONY | CMO & VP, Drug Deve ... | Option Exercise | A | 3.63 | 18,259 | 66,280 | 18,259 | |
| Jan 29 2007 | SGXP | SGX PHARMACEUTICAL ... | North Annette | VP, Corp Affairs & ... | Option Exercise | A | 3.63 | 25,489 | 92,525 | 25,489 | |
| Jan 29 2007 | SGXP | SGX PHARMACEUTICAL ... | North Annette | VP, Corp Affairs & ... | Option Exercise | A | 3.63 | 24,511 | 88,975 | 24,511 | |
| Jan 29 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Option Exercise | A | 3.63 | 34,118 | 123,848 | 34,118 | |
| Jan 29 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | CFO | Option Exercise | A | 3.63 | 15,882 | 57,652 | 15,882 | |
| Jan 29 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Option Exercise | A | 3.63 | 45,441 | 164,951 | 45,441 | |
| Jan 29 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Option Exercise | A | 3.63 | 34,559 | 125,449 | 34,559 | |
| Jan 29 2007 | SGXP | SGX PHARMACEUTICAL ... | Burley Stephen | CSO & SVP, Research | Option Exercise | A | 3.63 | 56,373 | 204,634 | 56,373 | |
| Jan 29 2007 | SGXP | SGX PHARMACEUTICAL ... | Burley Stephen | CSO & SVP, Research | Option Exercise | A | 3.63 | 43,627 | 158,366 | 43,627 | |
| Jan 29 2007 | SGXP | SGX PHARMACEUTICAL ... | GREY MICHAEL G | President & CEO | Option Exercise | A | 3.63 | 97,107 | 352,498 | 97,107 | |
| Jan 29 2007 | SGXP | SGX PHARMACEUTICAL ... | GREY MICHAEL G | President & CEO | Option Exercise | A | 3.63 | 52,893 | 192,002 | 52,893 | |
| Jan 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | Vice President, Dru ... | Option Exercise | M | 0.00 | 18,750 | 0 | 56,250 | |
| Jan 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | Vice President, Dru ... | Sell | S | 3.50 | 9,375 | 32,813 | 9,375 | 18.8 K to 9.4 K (-50.00 %) |
| Jan 16 2007 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | Vice President, Dru ... | Buy | M | 0.00 | 18,750 | 0 | 18,750 | 0 to 18.8 K |
| Jan 08 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,562 | 0 | 54,688 | |
| Jan 08 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | Chief Financial Off ... | Sell | S | 3.25 | 150 | 488 | 10,156 | 10.3 K to 10.2 K (-1.46 %) |
| Jan 08 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | Chief Financial Off ... | Sell | S | 3.20 | 631 | 2,019 | 10,306 | 10.9 K to 10.3 K (-5.77 %) |
| Jan 08 2007 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | Chief Financial Off ... | Buy | M | 0.00 | 1,562 | 0 | 10,937 | 9.4 K to 10.9 K (+16.66 %) |
| Dec 06 2006 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | Chief Financial Off ... | Option Exercise | M | 0.00 | 18,750 | 0 | 56,250 | |
| Dec 06 2006 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | Chief Financial Off ... | Sell | S | 2.99 | 9,375 | 28,031 | 9,375 | 18.8 K to 9.4 K (-50.00 %) |
| Dec 06 2006 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | Chief Financial Off ... | Buy | M | 0.00 | 18,750 | 0 | 18,750 | 0 to 18.8 K |
| Aug 15 2006 | SGXP | SGX PHARMACEUTICAL ... | RUGG TERENCE ANTHONY | VP, Chief Medical O ... | Option Exercise | A | 4.75 | 3,948 | 18,753 | 3,948 | |
| Aug 15 2006 | SGXP | SGX PHARMACEUTICAL ... | RUGG TERENCE ANTHONY | VP, Chief Medical O ... | Option Exercise | A | 4.75 | 71,052 | 337,497 | 71,052 | |
| Mar 13 2006 | SGXP | SGX PHARMACEUTICAL ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | A | 7.25 | 12,500 | 90,625 | 12,500 | |
| Mar 13 2006 | SGXP | SGX PHARMACEUTICAL ... | BAVP, L.P. | 10% Owner | Option Exercise | A | 7.25 | 12,500 | 90,625 | 12,500 | |
| Mar 13 2006 | SGXP | SGX PHARMACEUTICAL ... | BOCK LOUIS C | Director | Option Exercise | A | 7.25 | 12,500 | 90,625 | 12,500 | |
| Mar 10 2006 | SGXP | SGX PHARMACEUTICAL ... | Lathi Vijay K | Director | Option Exercise | A | 7.25 | 12,500 | 90,625 | 12,500 | |
| Mar 09 2006 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Option Exercise | A | 0.00 | 75,000 | 0 | 75,000 | |
| Mar 09 2006 | SGXP | SGX PHARMACEUTICAL ... | Reich Siegfried | VP, Drug Discovery | Option Exercise | A | 7.66 | 40,000 | 306,400 | 40,000 | |
| Mar 09 2006 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | Chief Financial Off ... | Option Exercise | A | 0.00 | 75,000 | 0 | 75,000 | |
| Mar 09 2006 | SGXP | SGX PHARMACEUTICAL ... | Myers W Todd | Chief Financial Off ... | Option Exercise | A | 7.66 | 50,000 | 383,000 | 50,000 | |
| Mar 09 2006 | SGXP | SGX PHARMACEUTICAL ... | Burley Stephen | Chf Sci Off & Sr VP ... | Option Exercise | A | 7.66 | 50,000 | 383,000 | 50,000 | |
| Mar 09 2006 | SGXP | SGX PHARMACEUTICAL ... | North Annette | VP, Legal Affairs & ... | Option Exercise | A | 7.66 | 60,000 | 459,600 | 60,000 | |
| Mar 09 2006 | SGXP | SGX PHARMACEUTICAL ... | GREY MICHAEL G | President & CEO | Option Exercise | A | 7.66 | 80,000 | 612,800 | 80,000 | |
| Feb 08 2006 | SGXP | SGX PHARMACEUTICAL ... | Lathi Vijay K | Director | Option Exercise | C | 0.00 | 495,368 | 0 | 0 | |
| Feb 08 2006 | SGXP | SGX PHARMACEUTICAL ... | Lathi Vijay K | Director | Option Exercise | C | 0.00 | 2,118,566 | 0 | 0 | |
| Feb 08 2006 | SGXP | SGX PHARMACEUTICAL ... | Lathi Vijay K | Director | Buy | P | 6.00 | 100,000 | 600,000 | 1,406,967 | 1.3 M to 1.4 M (+7.65 %) |
| Feb 08 2006 | SGXP | SGX PHARMACEUTICAL ... | Lathi Vijay K | Director | Buy | C | 0.00 | 247,684 | 0 | 1,306,967 | 1.1 M to 1.3 M (+23.38 %) |
| Feb 08 2006 | SGXP | SGX PHARMACEUTICAL ... | Lathi Vijay K | Director | Buy | C | 0.00 | 1,059,283 | 0 | 1,059,283 | 0 to 1.1 M |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | Atlas Venture Fund IV, L.P. | 10% Owner | Option Exercise | C | 0.00 | 783,968 | 0 | 0 | |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | Atlas Venture Fund IV, L.P. | 10% Owner | Option Exercise | C | 0.00 | 3,352,836 | 0 | 0 | |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | Atlas Venture Fund IV, L.P. | 10% Owner | Buy | C | 0.00 | 2,068,402 | 0 | 2,485,068 | 416.7 K to 2.5 M (+496.42 %) |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 783,968 | 0 | 0 | |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 3,352,836 | 0 | 0 | |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 2,068,402 | 0 | 2,485,068 | 416.7 K to 2.5 M (+496.42 %) |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | HENNEY CHRISTOPHER S | Director | Option Exercise | C | 0.00 | 7,426 | 0 | 0 | |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | HENNEY CHRISTOPHER S | Director | Option Exercise | C | 0.00 | 31,730 | 0 | 0 | |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | HENNEY CHRISTOPHER S | Director | Buy | C | 0.00 | 3,713 | 0 | 97,165 | 93.5 K to 97.2 K (+3.97 %) |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | HENNEY CHRISTOPHER S | Director | Buy | C | 0.00 | 15,865 | 0 | 93,452 | 77.6 K to 93.5 K (+20.45 %) |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | PAPADOPOULOS STELIOS | Director | Option Exercise | C | 0.00 | 13,626 | 0 | 0 | |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | PAPADOPOULOS STELIOS | Director | Option Exercise | C | 0.00 | 58,234 | 0 | 0 | |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | PAPADOPOULOS STELIOS | Director | Buy | C | 0.00 | 6,813 | 0 | 35,930 | 29.1 K to 35.9 K (+23.40 %) |
| Feb 07 2006 | SGXP | SGX PHARMACEUTICAL ... | PAPADOPOULOS STELIOS | Director | Buy | C | 0.00 | 29,117 | 0 | 29,117 | 0 to 29.1 K |
| Feb 06 2006 | SGXP | SGX PHARMACEUTICAL ... | BAVP, L.P. | 10% Owner | Option Exercise | C | 0.00 | 775,760 | 0 | 0 | |
| Feb 06 2006 | SGXP | SGX PHARMACEUTICAL ... | BAVP, L.P. | 10% Owner | Option Exercise | C | 0.00 | 3,317,734 | 0 | 0 | |
| Feb 06 2006 | SGXP | SGX PHARMACEUTICAL ... | BAVP, L.P. | 10% Owner | Buy | C | 0.00 | 387,880 | 0 | 2,046,747 | 1.7 M to 2 M (+23.38 %) |
| Feb 06 2006 | SGXP | SGX PHARMACEUTICAL ... | BAVP, L.P. | 10% Owner | Buy | C | 0.00 | 1,658,867 | 0 | 1,658,867 | 0 to 1.7 M |
| Feb 06 2006 | SGXP | SGX PHARMACEUTICAL ... | BOCK LOUIS C | Director | Option Exercise | C | 0.00 | 775,760 | 0 | 0 | |
| Feb 06 2006 | SGXP | SGX PHARMACEUTICAL ... | BOCK LOUIS C | Director | Option Exercise | C | 0.00 | 3,317,734 | 0 | 0 | |
| Feb 06 2006 | SGXP | SGX PHARMACEUTICAL ... | BOCK LOUIS C | Director | Buy | C | 0.00 | 387,880 | 0 | 2,046,747 | 1.7 M to 2 M (+23.38 %) |
| Feb 06 2006 | SGXP | SGX PHARMACEUTICAL ... | BOCK LOUIS C | Director | Buy | C | 0.00 | 1,658,867 | 0 | 1,658,867 | 0 to 1.7 M |
| Feb 03 2006 | SGXP | SGX PHARMACEUTICAL ... | FORMELA JEAN FRANCOIS | Director | Buy | P | 6.00 | 416,666 | 2,499,996 | 416,666 | 0 to 416.7 K |
| Feb 03 2006 | SGXP | SGX PHARMACEUTICAL ... | Atlas Venture Fund IV, L.P. | 10% Owner | Buy | P | 6.00 | 416,666 | 2,499,996 | 416,666 | 0 to 416.7 K |